George Bakris to Glucosides
This is a "connection" page, showing publications George Bakris has written about Glucosides.
Connection Strength
1.386
-
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014; 40(1):64-74.
Score: 0.499
-
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555.
Score: 0.189
-
Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page. Circulation. 2018 01 09; 137(2):130-133.
Score: 0.159
-
Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015 Mar; 38(3):429-30.
Score: 0.130
-
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014 Oct; 16(10):1016-27.
Score: 0.125
-
Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May; 8(5):330-9.
Score: 0.121
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013 May; 15(5):463-73.
Score: 0.114
-
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int. 2021 03; 99(3):750-762.
Score: 0.048